Background: Fermented foods rich in bioactive compounds have been proposed as potential strategy to combat non-communicable diseases. Among them is kombucha, a beverage fermented from sugared Camellia sinensis tea by a symbiotic culture of bacteria and yeasts (SCOBY). Recently, there has been an increased focus on assessing the actual effect of this beverage on human health. In this manner, this systematic review aimed to gather clinical evidence on the impact of kombucha consumption on human health. Methods: The databases Cochrane CENTRAL, MEDLINE/PubMed, and Embase® were searched, and the risk of bias tool used was the Critical Appraisal Tools outlined in the Joanna Briggs Institute. This review followed the PRISMA guidelines and was registered on PROSPERO (CRD42024599464). Results: Eight clinical trials were included (two pre- and post-interventions and six randomized controlled trials) with durations ranging from 10 days to 10 weeks. Two studies reported beneficial effects of kombucha on gastrointestinal symptoms, such as reduced intensity of constipation-related complaints. Two trials observed changes in gut microbiota composition, including increased abundance in Bacteroidota, Akkermansiaceae, Saccharomyces, and Weizmannia coagulans, alongside reductions in Ruminococcus, Dorea, and Rhodotorula. Moreover, five clinical trials evaluated glucose metabolism, evidencing inconsistent results, and other studies identified improvements in salivary microbiota composition and serum metabolomic profile. Conclusion: These findings suggest that kombucha consumption may provide health benefits, particularly in alleviating gastrointestinal symptoms, and demonstrates a modest capacity for modulating gut and salivary microbiota, as well as metabolomic profiles. Although the results are promising, the heterogeneity of the studies and the limited number of available clinical trials highlight the need for further robust research to confirm these effects.
31 October 2023 in International Journal of Food Sciences and Nutrition
We aimed to evaluate the association between caffeine intake and sleep time in Brazilian adults. This cross-sectional study was conducted with 6,356 participants from the Cohort of Universities of Minas Gerais (CUME Study). Data was collected through an online self-report questionnaire. Of the total, 31.9% of the participants had insufficient sleep. Women were found to sleep less than men (64.1 vs. 35.9%; p < 0.001), as well as being more likely to consume higher doses of caffeine (55.2%, p < 0.001). Coffee (35.7%), dark chocolate (25.2%), milk chocolate (15.2%), and diet soda (11.0%) were the foods that more contributed to caffeine intake. Individuals in the highest quartile of caffeine intake (87.0 - 572.0 mg/day) had a 19% higher prevalence of insufficient sleep compared with the lowest quartile (PR: 1.19; 95%CI: 1.08 - 1.31). Future studies are needed to investigate the genetic and hormonal factors involved in the interindividual response in this population.
Context: Genetic variants in the fat mass and obesity-associated gene (FTO) are consistently associated with obesity risk across populations. Methyl donor (MetD) nutrients, including vitamins B2, B6, B9, B12, choline, betaine, and methionine, participate in epigenetic mechanisms and may modulate gene expression related to obesity susceptibility. Objective: Whether MetD intake influences the association between FTO variants and body mass index (BMI) was evaluated in this systematic review and meta-analysis. Data Sources and Extraction: A systematic search was conducted in the PubMed, Embase, Scopus, Web of Science, and Cochrane databases up to May 2025, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Seven studies, comprising 1843 participants (67% women) aged 20-70 years, were included: 3 were cross-sectional studies, 3 were case-control studies, and 1 was a nonrandomized trial. The rs9939609 variant was analyzed in all studies, and 1 study examined additional FTO variants. None reported all MetD nutrients. Data Analysis: Random-effects models were applied to calculate pooled associations. Publication bias was examined using funnel plots and the Egger test. Meta-regression assessed whether MetD intake explained differences in mean BMI across genotypes. Results: Individuals homozygous for the risk allele of FTO single nucleotide polymorphisms had significantly higher BMI compared with nonrisk carriers (standardized mean difference = –0.31; 95% CI, –0.53 to –0.09). Meta-regression indicated that higher amounts of vitamin B12 intake attenuated the association between the risk genotype and BMI (β = –.050; 95% CI, –0.084 to –0.017; P = .008). No heterogeneity was detected (I2 = 0.0%; P = .983). Between-study variability was fully explained (τ2 = 0; residual I2 = 0.0%; adjusted R2 = 100%). No evidence of publication bias was observed (P = .169). Conclusion: This review and meta-analysis provide initial evidence that vitamin B12 intake exceeding population-level recommendations may modulate the association between FTO variants and BMI. These findings highlight the role of nutrition in genetic susceptibility to obesity and underscore the need for studies designed to address the limitations identified in this review to confirm these results and inform personalized nutrition strategies. Systematic Review Registration: PROSPERO registration no. CRD42024609752.